Brooklyn ImmunoTherapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat cancer patients. The company is headquartered in Brooklyn, New York.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-25.72M |
| Operating Margin | 0.00% |
| Return on Equity | -427.20% |
| Return on Assets | -35.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.26 |
| Price-to-Book | 1.10 |
| Price-to-Sales (TTM) | 87.41 |
| EV/Revenue | 87.41 |
| EV/EBITDA | 0.06 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $116.71M |
| Float | $34.05M |
| % Insiders | 0.00% |
| % Institutions | 27.48% |
Volatility is currently expanding
BlackRock Technology and Private Equity Term Trust aims for 80% tech exposure, blending public and private holdings, including a notable Anthropic stake. We analyze the fund's performance since inception and since the management change. We go over the rationale for our rating.
- Integrating AI and Web3 to establish institutional-grade blockchain infrastructure - Strategic 0% transfer fee policy to stimulate a hyper-connected digital economy
Investors are flipping back into buy mode, which has been a boon to the equity funds—especially on the tech side.
BlackRock Technology and Private Equity Term Trust is a Buy, offering a unique blend of AI infrastructure equities and private frontier AI holdings at a wide NAV discount. BTX's portfolio reset post-February 2025 delivers concentrated exposure to NVIDIA, AI supply chain leaders, and rare private stakes in Anthropic, OpenAI, PsiQuantum, and Deepgram. A 17%+ market price discount to NAV, paired with a 32% private equity allocation (mostly preferred stock), creates a compelling risk/reward profile for AI cycle participation.
